Experimental Research On The Development Of Extemporaneous Ointment ForThe Treatment Of Proctologic Diseases
Abstract
Hemorrhoids are the most common proctological diseases affecting an average of 12 people out of 100. Hemorrhoid affects more than 10 % of the adult population of the planet, and the proportion of the total number of proctological diseases is 40 %. Hemorrhoid is the most common reason to see a proctologist. Therefore, the problem of choosing the tactics of treatment of this category of patients remains relevant. If constipation is called “intellectual disease”, then hemorrhoid is called “royal disease”. Men and women suffer from this disease equally. In women, exacerbation of hemorrhoid often occurs during pregnancy, usually in the last trimester. Sooner or later, enlargement of the hemorrhoid appears in most people.
The objective of this work is the development of extemporaneous ointment for the treatment of proctologic diseases. To achieve this goal the following tasks were solved: the literature on the current state of such diseases as hemorrhoids has been analyzed and summarized; the range of medicines used to treat hemorrhoids has been analyzed. As a result the composition of the combined ointment for the treatment of hemorrhoid has been substantiated and its technology has been developed, the stability and microbiological purity of the created extemporaneous combined ointment has been studied.
Full Text:
PDFReferences
Yarnykh T.G., Tykhonov O.I., Melnyk G.M., et al. Pharmacopoeian aspects of suspensions preparation in pharmacy conditions. Asian Journal of Pharmaceutics. 2017; 11 (04): 859-864.
Rukhmakova O.A., Yarnykh T.G., Kovalenko S.N. The development of industrial technology of the ointment codenamed “Alergolik”. Research Journal of Pharmacy and Technology. 2017; 10 (12): 1994-1997.
Yarnykh T.G., Rukhmakova O.A. Peculiarities of the Technology, Quality Control, and Pharmaceutical Development of Extemporaneous Preparations for Children. Pharmaceutical Chemistry Journal. 2015; 49 (2): 122-124.
Yarnykh T.G., Garkavtseva O.A., Chushenko V.N. Development and standardization of dermalic ointment. Pharmaceutical Chemistry Journal. 2012; 45 (12): 750-753.
Chestnova T.V., Zilov V.G., Gladkikh P.G., et al. Combined effect of silver nanoparticles, ceftriaxone, and methyluracil during experimental purulent peritonitis. Bulletin of experimental biology and medicine. 2018; 165 (6): 777-778.
Fahad Malik, Jonatan Reyes, Bhavin Patel, et al. Hemorrhoid energy therapy for treatment of deep chronic anal fissures. ACG case reports journal. 2019; 6: 1-3.
George Latsios, Kostas Toutouzas, Alexios Antonopoulos, et al. Anesthetic ointment only (lidocaine/prilocaine) instead of injectable local lidocaine in trans-radial catheterization: A viable no-needle alternative. Journal of Interventional cardiology. 2017; 30: 382-386.
Jan Kestranek. Hemorrhoid management in women: the role of tribenoside+lidocaine. Drugs in context. 2019; 8: 1-7.
Brown S.R. Haemorrhoids: an update on management. Ther Adv Chronic Dis. 2017; 8 (10): s. 141-147.
Hollingshead J.R., Phillips R.K. Haemorrhoids: modern diagnosis and treatment. Postgrad Med. Journal. 2016; 92 (1083): 4-8.
Ahlund S., Radestad I., Zwedberg S.,et al. Haemorrhoids – a neglected problem faced by women after birth. Sex. Reprod. Health. 2018; 18: 30-36.
Lorenc Z, Gokle O. Tribenoside and lidocaine in the local treatment of haemorrhoids: an ovieriew of clinical evidence. Eur. Rev. Med. Pharmacol Sci. 2016; 20: 2742-2751.
Loshsiriwat V. Treatment of haemorrhoids: a coloproctologist’s view. World Journal Gastroenterol. 2015; 21: 9245-9252.
Abramowitz L., Weyandt G.h., Havlickova B., et al. The diagnosis and management of haemorrhoidal disease from a global perspective. Aliment Pharmacol Ther. 2010; 31 (Suppl 1): 1-58.
Refbacks
- There are currently no refbacks.
